Although surgical and catheter-based revascularization techniques have substan- tially improved today's therapeutic potential in ischemic heart disease, in the majority of patients treatment will be conservative for a number of reasons, the cost-effectiveness of non-pharmacological approaches being of major importance. During the last two decades, drug development for ischemic heart disease has been impressive and many new compounds have been added to our therapeutic armamentarium. Nevertheless, where mode of action is concerned, it is interesting to note that, despite all these efforts, we are still confined to three categories of drugs. Antithrombotics and platelet-active agents aside, these concern nitrates, betablocking drugs and calcium antagonists, agents which reduce ischemia by diminishing cardiac work or wall stress, . thereby affecting myocardial oxygen demand and/or by improving coronary blood flow. Alone or in combination, these agents have proved to be efficacious in the treatment of angina pectoris or other symptoms of ischemic heart disease in a number of patients, but certainly not in all. Moreover, as side-effects are often a problem with current antianginal compounds, the physician may find himself restricted in his therapeutic capabilities and in need of new and, preferably, alternative forms of pharmacological treatment.
Les informations fournies dans la section « Synopsis » peuvent faire référence à une autre édition de ce titre.
Vendeur : Ria Christie Collections, Uxbridge, Royaume-Uni
Etat : New. In. N° de réf. du vendeur ria9783798508613_new
Quantité disponible : Plus de 20 disponibles
Vendeur : BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Allemagne
Taschenbuch. Etat : Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Although surgical and catheter-based revascularization techniques have substan tially improved today's therapeutic potential in ischemic heart disease, in the majority of patients treatment will be conservative for a number of reasons, the cost-effectiveness of non-pharmacological approaches being of major importance. During the last two decades, drug development for ischemic heart disease has been impressive and many new compounds have been added to our therapeutic armamentarium. Nevertheless, where mode of action is concerned, it is interesting to note that, despite all these efforts, we are still confined to three categories of drugs. Antithrombotics and platelet-active agents aside, these concern nitrates, betablocking drugs and calcium antagonists, agents which reduce ischemia by diminishing cardiac work or wall stress, thereby affecting myocardial oxygen demand and/or by improving coronary blood flow. Alone or in combination, these agents have proved to be efficacious in the treatment of angina pectoris or other symptoms of ischemic heart disease in a number of patients, but certainly not in all. Moreover, as side-effects are often a problem with current antianginal compounds, the physician may find himself restricted in his therapeutic capabilities and in need of new and, preferably, alternative forms of pharmacological treatment. 76 pp. Englisch. N° de réf. du vendeur 9783798508613
Quantité disponible : 2 disponible(s)
Vendeur : Kennys Bookshop and Art Galleries Ltd., Galway, GY, Irlande
Etat : New. This volume addresses a novel concept in antiischemic therapy, sinus node inhibition. The sinus node inhibitors which have thus far been developed, including the clonidine-derivative alinidine, falipamil and the benzazepinone derivative UL FS 49, are discussed in detail. Editor(s): Hjalmarson, A.; Remme, W. J. Num Pages: 64 pages, 3 black & white illustrations, biography. BIC Classification: MJD; MMG. Category: (P) Professional & Scholarly; (UP) Postgraduate. Dimension: 244 x 170 x 4. Weight in Grams: 137. . 1991. Paperback. . . . . N° de réf. du vendeur V9783798508613
Quantité disponible : 15 disponible(s)
Vendeur : moluna, Greven, Allemagne
Kartoniert / Broschiert. Etat : New. N° de réf. du vendeur 5316945
Quantité disponible : Plus de 20 disponibles
Vendeur : Books Puddle, New York, NY, Etats-Unis
Etat : New. pp. 76. N° de réf. du vendeur 261537254
Quantité disponible : 4 disponible(s)
Vendeur : preigu, Osnabrück, Allemagne
Taschenbuch. Etat : Neu. Sinus node inhibitors | A new concept in angina pectoris | W. J. Remme (u. a.) | Taschenbuch | viii | Englisch | 1991 | Steinkopff | EAN 9783798508613 | Verantwortliche Person für die EU: Steinkopff, Dietrich Verlag in Springer Science + Business M, Tiergartenstr. 15-17, 69121 Heidelberg, juergen[dot]hartmann[at]springer[dot]com | Anbieter: preigu. N° de réf. du vendeur 102112532
Quantité disponible : 5 disponible(s)
Vendeur : Revaluation Books, Exeter, Royaume-Uni
Paperback. Etat : Brand New. 1st edition. 76 pages. Delaware language. 9.61x6.69x0.18 inches. In Stock. N° de réf. du vendeur x-3798508615
Quantité disponible : 2 disponible(s)
Vendeur : buchversandmimpf2000, Emtmannsberg, BAYE, Allemagne
Taschenbuch. Etat : Neu. This item is printed on demand - Print on Demand Titel. Neuware -Although surgical and catheter-based revascularization techniques have substan tially improved today's therapeutic potential in ischemic heart disease, in the majority of patients treatment will be conservative for a number of reasons, the cost-effectiveness of non-pharmacological approaches being of major importance. During the last two decades, drug development for ischemic heart disease has been impressive and many new compounds have been added to our therapeutic armamentarium. Nevertheless, where mode of action is concerned, it is interesting to note that, despite all these efforts, we are still confined to three categories of drugs. Antithrombotics and platelet-active agents aside, these concern nitrates, betablocking drugs and calcium antagonists, agents which reduce ischemia by diminishing cardiac work or wall stress, thereby affecting myocardial oxygen demand and/or by improving coronary blood flow. Alone or in combination, these agents have proved to be efficacious in the treatment of angina pectoris or other symptoms of ischemic heart disease in a number of patients, but certainly not in all. Moreover, as side-effects are often a problem with current antianginal compounds, the physician may find himself restricted in his therapeutic capabilities and in need of new and, preferably, alternative forms of pharmacological treatment.Steinkopff Dr. Dietrich V, Poststr. 9, 64293 Darmstadt 76 pp. Englisch. N° de réf. du vendeur 9783798508613
Quantité disponible : 1 disponible(s)
Vendeur : AHA-BUCH GmbH, Einbeck, Allemagne
Taschenbuch. Etat : Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - Although surgical and catheter-based revascularization techniques have substan tially improved today's therapeutic potential in ischemic heart disease, in the majority of patients treatment will be conservative for a number of reasons, the cost-effectiveness of non-pharmacological approaches being of major importance. During the last two decades, drug development for ischemic heart disease has been impressive and many new compounds have been added to our therapeutic armamentarium. Nevertheless, where mode of action is concerned, it is interesting to note that, despite all these efforts, we are still confined to three categories of drugs. Antithrombotics and platelet-active agents aside, these concern nitrates, betablocking drugs and calcium antagonists, agents which reduce ischemia by diminishing cardiac work or wall stress, thereby affecting myocardial oxygen demand and/or by improving coronary blood flow. Alone or in combination, these agents have proved to be efficacious in the treatment of angina pectoris or other symptoms of ischemic heart disease in a number of patients, but certainly not in all. Moreover, as side-effects are often a problem with current antianginal compounds, the physician may find himself restricted in his therapeutic capabilities and in need of new and, preferably, alternative forms of pharmacological treatment. N° de réf. du vendeur 9783798508613
Quantité disponible : 1 disponible(s)
Vendeur : Kennys Bookstore, Olney, MD, Etats-Unis
Etat : New. This volume addresses a novel concept in antiischemic therapy, sinus node inhibition. The sinus node inhibitors which have thus far been developed, including the clonidine-derivative alinidine, falipamil and the benzazepinone derivative UL FS 49, are discussed in detail. Editor(s): Hjalmarson, A.; Remme, W. J. Num Pages: 64 pages, 3 black & white illustrations, biography. BIC Classification: MJD; MMG. Category: (P) Professional & Scholarly; (UP) Postgraduate. Dimension: 244 x 170 x 4. Weight in Grams: 137. . 1991. Paperback. . . . . Books ship from the US and Ireland. N° de réf. du vendeur V9783798508613
Quantité disponible : 15 disponible(s)